Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IASLC TTLC 2022 | The future of anti-PD-1 therapies in the NSCLC treatment landscape

Nathan Pennell, MD, PhD, Cleveland Clinic, Cleveland, OH, comments on advances in the use of PD-1 inhibitor in advanced non-small cell lung cancer (NSCLC). Whilst pembrolizumab plus chemotherapy has been successfully used in the clinic following data from the KEYNOTE-189 (NCT02578680) and KEYNOTE-407 (NCT02775435) trials, studies assessing anti-PD-1 with anti-CTLA-4 antibodies have failed to yield superior outcomes. Prof. Pennell additionally highlights the unreliability of trials that exclusively use chemotherapy as the standard of care. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).